Key result
The SARS-CoV-2 nucleocapsid R203K/G204R mutations were associated with significantly higher viral loads in COVID-19 patients, increasing the mean log10 viral copy number by 1.33.
Why the study?
Monitoring SARS-CoV-2 spread and evolution through genome sequencing is essential in handling the COVID-19 pandemic.
Does the R203K/G204R mutation in the SARS-CoV-2 nucleocapsid protein increase viral load and disease severity in COVID-19 patients?
Observational (n=892)
Yes
Does the R203K/G204R mutation in the SARS-CoV-2 nucleocapsid protein increase viral load and disease severity in COVID-19 patients?
Mean Difference: 1.33 (95% CI 0.72–1.93)
The R203K/G204R mutations in the SARS-CoV-2 nucleocapsid protein are associated with higher viral loads, increased disease severity, and dysregulated host interferon responses.
May inform variant surveillance; hypothesis-generating and requires prospective validation before clinical adoption.
Monitoring SARS-CoV-2 spread and evolution through genome sequencing is essential in handling the COVID-19 pandemic. Here, we sequenced 892 SARS-CoV-2 genomes collected from patients in Saudi Arabia from March to August 2020. We show that two consecutive mutations (R203K/G204R) in the nucleocapsid (N) protein are associated with higher viral loads in COVID-19 patients. Our comparative biochemical analysis reveals that the mutant N protein displays enhanced viral RNA binding and differential interaction with key host proteins. We found increased interaction of GSK3A kinase simultaneously with hyper-phosphorylation of the adjacent serine site (S206) in the mutant N protein. Furthermore, the host cell transcriptome analysis suggests that the mutant N protein produces dysregulated interferon response genes. Here, we provide crucial information in linking the R203K/G204R mutations in the N protein to modulations of host-virus interactions and underline the potential of the nucleocapsid protein as a drug target during infection.
No takes yet. Share an insight, caveat, or question.
Mourier et al. (2022) conducted an observational in COVID-19 (n=892). SARS-CoV-2 nucleocapsid (N) protein R203K/G204R mutations vs. SARS-CoV-2 without R203K/G204R mutations was evaluated on log10(viral copy number) (MD 1.33, 95% CI 0.72-1.93). The SARS-CoV-2 nucleocapsid R203K/G204R mutations were associated with significantly higher viral loads in COVID-19 patients, increasing the mean log10 viral copy number by 1.33.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: